BidaskClub lowered shares of USANA Health Sciences, Inc. (NYSE:USNA) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Separately, Pivotal Research upped their target price on shares of USANA Health Sciences from $70.00 to $80.00 and gave the stock a buy rating in a research report on Wednesday, October 25th.

Shares of USANA Health Sciences (NYSE:USNA) traded down $0.20 on Thursday, reaching $64.85. 68,626 shares of the company’s stock traded hands, compared to its average volume of 132,966. The company has a market capitalization of $1,585.26, a price-to-earnings ratio of 17.16 and a beta of 1.07.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.54%. The company had revenue of $261.77 million for the quarter, compared to analyst estimates of $259.52 million. During the same period in the prior year, the business posted $2.40 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. sell-side analysts expect that USANA Health Sciences will post 3.7 earnings per share for the current fiscal year.

WARNING: “BidaskClub Lowers USANA Health Sciences, Inc. (USNA) to Sell” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/bidaskclub-lowers-usana-health-sciences-inc-usna-to-sell/1680588.html.

USANA Health Sciences announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, July 25th that allows the company to repurchase $64.60 million in outstanding shares. This repurchase authorization allows the company to buy up to 46% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

In other USANA Health Sciences news, insider Daniel A. Macuga sold 5,751 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $60.00, for a total value of $345,060.00. Following the sale, the insider now owns 2,077 shares of the company’s stock, valued at $124,620. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel A. Macuga sold 11,992 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $59.00, for a total transaction of $707,528.00. Following the completion of the sale, the insider now directly owns 11,992 shares in the company, valued at approximately $707,528. The disclosure for this sale can be found here. Insiders sold 542,489 shares of company stock worth $33,489,137 in the last ninety days. Insiders own 53.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in USNA. Renaissance Technologies LLC lifted its stake in shares of USANA Health Sciences by 10.6% during the second quarter. Renaissance Technologies LLC now owns 1,948,266 shares of the company’s stock valued at $124,884,000 after buying an additional 186,600 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of USANA Health Sciences by 711.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 91,409 shares of the company’s stock valued at $5,859,000 after buying an additional 80,145 shares during the period. FMR LLC lifted its stake in shares of USANA Health Sciences by 3.9% during the second quarter. FMR LLC now owns 1,598,143 shares of the company’s stock valued at $102,441,000 after buying an additional 60,033 shares during the period. Old Mutual Global Investors UK Ltd. lifted its stake in shares of USANA Health Sciences by 29.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 239,680 shares of the company’s stock valued at $15,363,000 after buying an additional 54,831 shares during the period. Finally, Schroder Investment Management Group lifted its stake in shares of USANA Health Sciences by 9.0% during the second quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock valued at $36,734,000 after buying an additional 47,448 shares during the period. 44.62% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.